<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241315</url>
  </required_header>
  <id_info>
    <org_study_id>OTL-2019-OTL38-007</org_study_id>
    <nct_id>NCT04241315</nct_id>
  </id_info>
  <brief_title>ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting</brief_title>
  <acronym>Elucidate</acronym>
  <official_title>A Phase 3, Randomized,Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>On Target Laboratories, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinipace Worldwide</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>On Target Laboratories, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, multi-center, single dose, open-label, exploratory study in suspected lung&#xD;
      cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/PET/MRI or other&#xD;
      imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near&#xD;
      Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to&#xD;
      assess the safety and tolerability of single intravenous doses of OTL38.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2020</start_date>
  <completion_date type="Anticipated">October 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically Significant Events (CSE)</measure>
    <time_frame>1 day</time_frame>
    <description>The primary efficacy endpoint is the proportion of patients who demonstrate at least one CSE as a result of utilizing OTL-38 and Near Infrared Imaging.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Near-Infrared Imaging group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Imaging Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients in this arm will receive OTL38 for injection but will not receive intraoperative imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTL38 for Injection</intervention_name>
    <description>Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL</description>
    <arm_group_label>Near-Infrared Imaging group</arm_group_label>
    <arm_group_label>No Imaging Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Near infrared camera imaging system</intervention_name>
    <description>Near infrared camera imaging system</description>
    <arm_group_label>Near-Infrared Imaging group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and Female subjects 18 years of age and older&#xD;
&#xD;
          2. Have a primary diagnosis, or a high clinical suspicion, of cancer in the lung&#xD;
             warranting surgery based on CT/PET or other imaging&#xD;
&#xD;
          3. Are scheduled to undergo surgical thoracoscopy for diagnostic wedge resection followed&#xD;
             by anatomic lung resection&#xD;
&#xD;
          4. Female subjects of childbearing potential or less than 2 years postmenopausal agree to&#xD;
             use an acceptable form of contraception from the time of signing informed consent&#xD;
             until 30 days after study completion&#xD;
&#xD;
          5. Ability to understand the requirements of the study, provide written informed consent&#xD;
             and authorization of use and disclosure of protected health information, and agree to&#xD;
             abide by the study restrictions and to return for the required assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous exposure to OTL38&#xD;
&#xD;
          2. Any medical condition that in the opinion of the investigators could potentially&#xD;
             jeopardize the safety of the subject&#xD;
&#xD;
          3. History of anaphylactic reactions to folate, including synthetic folic acid&#xD;
             (pteroylmonoglutamic acid) and contrast agents containing indocyanine green for near&#xD;
             infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will&#xD;
             require evaluation.&#xD;
&#xD;
          4. History of allergy to any of the components of OTL38, including folic acid&#xD;
&#xD;
          5. A positive serum pregnancy test at Screening or a positive urine pregnancy test on the&#xD;
             day of surgery or day of admission for female subjects of childbearing potential&#xD;
&#xD;
          6. Clinically significant abnormalities on electrocardiogram (ECG) at screening.&#xD;
&#xD;
          7. Presence of any psychological, familial, sociological condition or geographical&#xD;
             challenges potentially hampering compliance with the study protocol and follow-up&#xD;
             schedule&#xD;
&#xD;
          8. Impaired renal function defined as eGFR&lt; 50 mL/min/1.73m2&#xD;
&#xD;
          9. Impaired liver function defined as values &gt; 3x the upper limit of normal (ULN) for&#xD;
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline&#xD;
             phosphatase (ALP), or &gt;2x ULN for total bilirubin except in subjects with Gilbert's&#xD;
             syndrome.&#xD;
&#xD;
         10. Received an investigational agent in another investigational drug or vaccine trial&#xD;
             within 30 days prior to the administration of study drug&#xD;
&#xD;
         11. Known sensitivity to fluorescent light&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Singhal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tommy Lee</last_name>
    <phone>7655884547</phone>
    <email>Tlee@ontargetlabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stamford</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ed Hatton</last_name>
      <email>ehatton@stamhealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Ebright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>55242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Ricks-McGillin</last_name>
      <email>joan-ricks@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Kalpaj Parekh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Barnett</last_name>
      <email>shbailey@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Rishindra Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Travis Fisher</last_name>
      <email>fisher.travis1@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Shanda Blackmon, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Aritonovich</last_name>
      <email>jessica.aritonovich@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Benny Weksler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Allen</last_name>
      <email>lja9d@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Martin, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron Cossette</last_name>
      <email>aaron.cossette@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Brian Louie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intraoperative Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

